Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Eli Lilly’s (NYSE: LLY) latest acquisition has electrified the biotech world—and sent a clear message that gene editing is no ...

Canaccord downgraded Verve Therapeutics (VERV) to Hold from Buy with a price target of $13, down from $39, after Eli Lilly (LLY) announced a definitive agreement to acquire Verve. Lilly will commence ...

BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise before the transaction is ...

Verve Therapeutics is at the forefront of gene-editing technology applied to cardiovascular diseases. The company’s lead asset, VERVE-102, targets PCSK9 to reduce LDL cholesterol levels in ...

Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.

Verve Therapeutics (NASDAQ:VERV – Get Free Report) was downgraded by stock analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued on Wednesday ...

Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click for more on LLY and VERV.

Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to acquire Verve. Given that PCSK9 binds to low-density lipoprotein (LDL ...